Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT05111444 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Camrelizumab
DRUG: Pyrotinib
DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Paclitaxel
DRUG: S-1

Sponsor

Fudan University